All

What are you looking for?

All
Projects
Results
Organizations

Quick search

  • Projects supported by TA ČR
  • Excellent projects
  • Projects with the highest public support
  • Current projects

Smart search

  • That is how I find a specific +word
  • That is how I leave the -word out of the results
  • “That is how I can find the whole phrase”

Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

The result's identifiers

  • Result code in IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00843989%3A_____%2F10%3A00103135" target="_blank" >RIV/00843989:_____/10:00103135 - isvavai.cz</a>

  • Result on the web

    <a href="http://dx.doi.org/10.1542/peds.2008-1036" target="_blank" >http://dx.doi.org/10.1542/peds.2008-1036</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1542/peds.2008-1036" target="_blank" >10.1542/peds.2008-1036</a>

Alternative languages

  • Result language

    angličtina

  • Original language name

    Motavizumab for prophylaxis of respiratory syncytial virus in high-risk children: a noninferiority trial

  • Original language description

    OBJECTIVE: Palivizumab reduces respiratory syncytial virus (RSV) hospitalization in children at high risk by similar to 50% compared with placebo. We compared the efficacy and safety of motavizumab, an investigational monoclonal antibody with enhanced anti-RSV activity in preclinical studies, with palivizumab. METHODS: This randomized, double-blind, multinational, phase 3, noninferiority trial assessed safety and RSV hospitalization in 6635 preterm infants aged <= 6 months at enrollment or children aged<= 24 months with chronic lung disease of prematurity who received 15 mg/kg palivizumab or motavizumab monthly. Secondary end points included outpatient medically attended lower respiratory tract infections (MALRIs), RSV-specific LRIs, otitis media, antibiotic use, development of antimotavizumab antibodies, and motavizumab serum concentrations. RESULTS: Motavizumab recipients had a 26% relative reduction in RSV hospitalization compared with palivizumab recipients, achieving noninferiori

  • Czech name

  • Czech description

Classification

  • Type

    J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)

  • CEP classification

    FG - Paediatrics

  • OECD FORD branch

Result continuities

  • Project

  • Continuities

    N - Vyzkumna aktivita podporovana z neverejnych zdroju

Others

  • Publication year

    2010

  • Confidentiality

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Data specific for result type

  • Name of the periodical

    Pediatrics

  • ISSN

    0031-4005

  • e-ISSN

  • Volume of the periodical

    125

  • Issue of the periodical within the volume

    1

  • Country of publishing house

    US - UNITED STATES

  • Number of pages

    17

  • Pages from-to

    "e35"-"e51"

  • UT code for WoS article

    000273348000034

  • EID of the result in the Scopus database